地舒单抗联合四烯甲萘醌治疗老年骨质疏松患者的疗效及安全性

doi:10.3969/j.issn.1003-9198.2026.10.009

摘要/Abstract

摘要： 目的探讨地舒单抗联合四烯甲萘醌治疗老年骨质疏松患者的临床疗效及安全性。方法选取2022年3月至2025年3月期间无锡市第九人民医院收治的183例老年骨质疏松患者为研究对象,根据治疗方式不同分为对照组(n=92)和试验组(n=91),对照组给予地舒单抗治疗,试验组在对照组基础上加用四烯甲萘醌。6个月后比较2组患者的临床疗效、骨密度、骨碱性磷酸酶(BALP)、β-胶原降解产物(β-CTX)、Ⅰ型原胶原N-端前肽(PⅠNP)、血钙(Ca)、血磷(P)及Oswestry功能障碍指数(ODI)评分,并观察不良反应的发生情况。结果治疗后,试验组的总有效率明显高于对照组(95.6% 比72.8%,P＜0.01)。2组治疗后骨密度和骨代谢生化标志物水平均较治疗前明显改善(P＜0.05),试验组L2~L4和髋部的骨密度、血清Ca水平均明显高于对照组(P＜0.05),血清BALP、β-CTX、PⅠNP、P水平和ODI评分明显低于对照组(P＜0.05)。2组在治疗期间未出现肌肉痛、低钙血症、胃肠道反应等不良反应。结论地舒单抗联合四烯甲萘醌能够有效改善老年骨质疏松患者的骨代谢状态,增加骨密度,且安全性良好,具有一定的临床推广价值。

关键词: 骨质疏松, 地舒单抗, 四烯甲萘醌, 骨密度, 骨代谢指标

Abstract: Objective To evaluate the clinical efficacy and safety of denosumab combined with menatetrenone in the elderly patients with osteoporosis. Methods A total of 183 elderly patients with osteoporosis admitted to Wuxi Ninth People’s Hospital from March 2022 to March 2025 were enrolled. All the patients were divided into a control group (n=92) and a experimental group (n=91) according to different treatment regimens. The control group was given denosumab, and the experimental group was treated with denosumab combined with menatetrenone.The clinical efficacy, bone mineral density (BMD), bone metabolism biochemical markers such as bone alkaline phosphatase (BALP), β-cross-linked C-telopeptide of type Ⅰ collagen (β-CTX), N-terminal propeptide of type Ⅰ procollagen (PⅠNP), serum calcium (Ca), and serum phosphorus (P), Oswestry Disability Index (ODI) score, and incidence of adverse reactions were observed and compared between the two groups after six months. Results After treatment, the total effective rate in the experimental group was significantly higher than that in the control group (95.6% vs 72.8%,P<0.01). The levels of BMD of lumbar spine L2-L4 and hip and bone metabolism biochemical markers were improved in two groups after treatment. The BMD levels of lumbar spine L2-L4 and hip and serum calcium level were significantly higher, while the serum levels of BALP, β-CTX, PⅠNP, P and ODI score were significantly lower in the experimental group than those in the control group (P<0.05). No obvious adverse drug reactions such as myalgia, hypocalcemia, or gastrointestinal reactions occurred in two groups during the treatment period. Conclusions Denosumab combined with menatetrenone can effectively improve bone metabolic status, increase BMD, and shows good safety in the elderly patients with osteoporosis, which has certain clinical promotion value.

Key words: osteoporosis, denosumab, menatetrenone, bone mineral density, bone metabolism markers

中图分类号:

R681

刘少昊, 尤晓红, 赵晓杰, 周聪, 杨海华. 地舒单抗联合四烯甲萘醌治疗老年骨质疏松患者的疗效及安全性[J]. 实用老年医学, 2026, 40(10): 1024-1027.

LIU Shaohao, YOU Xiaohong, ZHAO Xiaojie, ZHOU Cong, YANG Haihua. Efficacy and safety of denosumab combined with menatetrenone in the elderly patients with osteoporosis[J]. Practical Geriatrics, 2026, 40(10): 1024-1027.

参考文献

[1] 郭艳峰, 周伯炜, 庞龙, 等. 老年骨质疏松症患者铁蛋白与骨代谢指标及骨折风险的关系研究[J]. 临床和实验医学杂志, 2025, 24(8): 840-843.
[2] DAS T, JUBAYER BISWAS M A A, MONDAL P, et al. Osteoporosis incidence and its associated factors in the older Korean population: findings from a population-based cohort study[J]. Arch Osteoporos, 2024, 19(1): 111.
[3] 陶蓓, 孙立昊, 杨毓莹, 等. 原发性骨质疏松症和各种钙磷代谢异常疾病诊治中的几个关键问题[J]. 中华医学杂志, 2025, 105(1): 10-14.
[4] 闻燕, 王悦, 李江花, 等. 地舒单抗联合碳酸钙D3及骨化三醇对老年骨质疏松患者骨密度及骨代谢指标影响的研究[J]. 转化医学杂志, 2025, 14(3): 41-44.
[5] 朱衍, 邱雷雨, 周筱. 四烯甲萘醌联合PKP术治疗骨质疏松性椎体压缩骨折患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(10): 1409-1413.
[6] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-443.
[7] NAG D S. Assessing the risk: scoring systems for outcome prediction in emergency laparotomies[J]. Biomedicine: Taipei, 2015, 5(4): 20.
[8] 程继伟, 王振林, 刘伟, 等. Oswestry功能障碍指数的改良及信度和效度检验[J]. 中国脊柱脊髓杂志, 2017, 27(3): 235-241.
[9] SCHWARCZ Y, YANOVER C, ROUACH V, et al. Non-osteoporotic fractures are associated with increased risk of subsequent major osteoporotic fractures[J]. Osteoporos Int, 2024, 35(10): 1839-1847.
[10] 王学宗, 路雨, 丁道芳, 等. 膝骨关节炎合并骨质疏松患者的维生素D及骨代谢特点[J]. 中国骨伤, 2025, 38(4): 352-357.
[11] 李俊伟, 秦凡, 罗宇茜. 老年脊柱退行性改变伴骨质疏松症患者血尿酸、脂代谢及维生素D的变化与预测价值[J]. 川北医学院学报, 2025, 40(7): 905-908.
[12] HU M, ZHANG Y, GUO J, et al. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis[J]. Front Endocrinol, 2023, 14:1188969.
[13] 刘盈, 周满如, 黎卓熹, 等. Denosumab治疗类风湿性关节炎的研究现状[J]. 中国临床药理学杂志, 2021, 37(8): 1012-1015.
[14] CHEN Y, JIA L, HAN T, et al. Osteoporosis treatment: current drugs and future developments[J]. Front Pharmacol, 2024, 15: 1456796.
[15] ZHANG N, ZHANG Z K, YU Y, et al. Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy[J]. Front Cell Dev Biol, 2020, 8: 325.
[16] MILLER M J, KROENKE M A, BARGER T, et al. Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies[J]. J Immunol Meth, 2025, 540: 113864.
[17] 蒋益忠, 林丽娟, 辛海量, 等. 四烯甲萘醌保护成骨细胞氧化损伤的作用研究[J]. 药学实践杂志, 2020, 38(6): 523-527.
[18] 邱宏韬, 林青, 赖文强, 等. 四烯甲萘醌软胶囊联合益肾固本祛痛汤治疗骨质疏松患者临床疗效[J]. 海南医学院学报, 2019, 25(14): 1092-1095.
[19] 余黎吉, 伍丹丹, 杜晓敏, 等. 地舒单抗联合特立帕肽治疗绝经后骨质疏松的临床研究[J]. 中国计划生育和妇产科, 2025, 17(1): 84-86, 91.
[20] MURAHASHI Y, TERAMOTO A, JIMBO S, et al. Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty[J]. Knee, 2020, 27(2): 580-586.